CLINICAL_TRIALS ClinicalTrials.gov record update

Single Arm Phase II Study of Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder as Second Line Treatment

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01382706
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:11.892130+00:00
Published At: 2025-10-09T00:00:00+00:00
Record Updated At: 2025-10-09
Results Posted At: 2025-10-09
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Recurrent Bladder Cancer", "Stage III Bladder Cancer", "Stage IV Bladder Cancer", "Transitional Cell Carcinoma of the Bladder"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-10-09"
protocolSection.identificationModule.nctId: "NCT01382706"
protocolSection.identificationModule.officialTitle: "Single Arm Phase II Study of Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder as Second Line Treatment"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-10-09"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.